Purpose Primary graft dysfunction (PGD) is the main cause of mortality during the first month and the second one within the first year after lung transplantation (LT). Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have been proposed as an effective class of drugs to reduce serum cholesterol levels due to their immunomodulatory and anti-inflammatory effects unrelated to their cholesterol-lowering function. We hypothesized that preoperative statin therapy is associated with decreased incidence of PGD after LT. Methods Retrospective analysis of all consecutive adult LTs performed in a university transplant center between 2010 and 2017. Comparison between groups according to the recipient previous use of statins was carried out. Factors associated with the development of PGD and PGD grade 3 were analyzed using Chi square and U-Mann Whitney Test. Logistic regression model was built including those variables with p≤0.1 in the univariate analysis. Significance level p Results A total of 474 adult LT recipients were followed, 54 of them (11%) under statins treatment. Statins group (SG) were older (59 vs 55;p=0.003), with higher prevalence of hypertension (HT)(37% vs 16%; p Conclusion Recipient´s preoperative use of statins is associated with a decreased risk to develop PGD in our series. Prospective and multicentric studies are needed to confirm such results.